
The FDA has approved Novartis’ Signifor (pasireotide) for the treatment of a rare and life-threatening hormonal disorder. The US Food …
Novartis’ injection Signifor has been approved by the FDA to treat Cushing’s disease, a rare but serious endocrine disorder affecting …
A European committee has recommended Novartis’ Signifor for the treatment of a rare, debilitating endocrine disorder. The European Committee for …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

